Guardian completes Signature Mapping trial
Healthcare technology and security screening device manufacturer Guardian Technologies reported the successful completion of a clinical study involving the evaluation of its Signature Mapping mammography computer-assisted diagnosis (CAD) application to the Digital Database for Screening Mammography (DDSM) project, an online database of mammographic x-ray exams.

According to the Herndon, Va.-based Guardian, the study demonstrated that its Signature Mapping technology achieved a 97.5 percent detection rate (sensitivity) on cancer cases, with just 2.5 percent false negatives (cancer lesions undetected). On non-cancer cases, Signature Mapping accurately specified “no cancer” in 98.75 percent of the images, with a false positive rate of just 1.25 percent.

Guardian’s study of the DDSM database analyzed 160 images from 40 normal cases, and 80 images from 40 cancer cases. The company said that the cancer group was selected on the basis of its wide range of size and subtlety of speculated tumors.

The DDSM collection used in the study was created by the University of South Florida in collaboration with Massachusetts General Hospital, Sandia National Laboratories, and Wake Forest University School of Medicine, with grant funding from the Breast Cancer Research Program of the U.S. Army Medical Research and Materiel Command, according to Guardian.